Statistik Asas
| LEI | 549300CLUMLZXIHU7X22 |
| CIK | 1615219 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Flex Pharma, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Com |
|
| August 26, 2025 |
UNAUDITED PRO FORMA CONSOLIDATED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONSOLIDATED COMBINED FINANCIAL INFORMATION The following unaudited pro forma consolidated combined financial information is provided to aid you in your analysis of the financial aspects of the Merger and Financing Transactions and presents the combination of the financial information of Salarius and Decoy adjusted to give effect to the Merger and Financing Transac |
|
| August 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (C |
|
| August 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Com |
|
| August 22, 2025 |
Exhibit 99.2 Consolidated Financial Statements Three and six months ended June 30, 2025, 2024 (unaudited) and year end December 31, 2024 DECOY THERAPEUTICS, INC. Contents Page Consolidated Financial Statements Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 F-1 Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 (unaudit |
|
| August 22, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-266589 PROSPECTUS SUPPLEMENT (To the Prospectus Dated August 16, 2022) Up to $2,600,000 Common Stock We previously entered into an At the Market Offering Agreement dated as of February 5, 2021, or the sales agreement, with Ladenburg Thalmann & Co. Inc., or Ladenburg, relating to shares of our common stock, par value $0.0001 per share, offered b |
|
| August 22, 2025 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 99.1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Shareholders of Decoy Therapeutics, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Decoy Therapeutics, Inc. (“the Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations, shareholders’ equity, and cash |
|
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Com |
|
| August 22, 2025 |
UNAUDITED PRO FORMA CONSOLIDATED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONSOLIDATED COMBINED FINANCIAL INFORMATION The following unaudited pro forma consolidated combined financial information is provided to aid you in your analysis of the financial aspects of the Merger and Financing Transactions and presents the combination of the financial information of Salarius and Decoy adjusted to give effect to the Merger and Financing Transac |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Com |
|
| August 15, 2025 |
Calculation of Filing Fee Tables S-3 Salarius Pharmaceuticals, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forw |
|
| August 15, 2025 |
As filed with the Securities and Exchange Commission on August 15, 2025 As filed with the Securities and Exchange Commission on August 15, 2025 Registration No. |
|
| August 15, 2025 |
CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SALARIUS PHARMACEUTICALS, INC. |
|
| August 15, 2025 |
Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split HOUSTON, August 14, 2025 – Salarius Pharmaceuticals, Inc. |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Com |
|
| August 12, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 00 |
|
| August 8, 2025 |
Form of Series A Common Warrant to Purchase Shares of Common Stock Exhibit 4.12 SERIES A COMMON STOCK PURCHASE WARRANT SALARIUS PHARMACEUTICALS, INC. Warrant Shares: Issue Date: , 2025 CUSIP: ISIN: THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO., or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| August 8, 2025 |
As filed with the Securities and Exchange Commission on August 7, 2025 As filed with the Securities and Exchange Commission on August 7, 2025 Registration No. |
|
| August 8, 2025 |
Form of Series B Common Warrant to Purchase Shares of Common Stock Exhibit 4.13 SERIES B COMMON STOCK PURCHASE WARRANT SALARIUS PHARMACEUTICALS, INC. Warrant Shares: Issue Date: , 2025 CUSIP: ISIN: THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO., or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| August 8, 2025 |
Form of Representative Warrant Exhibit 4.10 REPRESENTATIVE COMMON STOCK PURCHASE WARRANT SALARIUS PHARMACEUTICALS, INC. Warrant Shares: Issue Date: , 2025 THIS REPRESENTATIVE COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, , or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the d |
|
| August 5, 2025 |
slrx-decoyinvestorpresen © 2020 Salarius Pharmaceuticals, Inc. Confidential NASDAQ:SLRX Investor Presentation Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Number 333-284368 August 5, 2025 Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Salarius Pharmaceu |
|
| July 31, 2025 |
Form of Underwriting Agreement Exhibit 1.1 SHARES OF COMMON STOCK, PRE-FUNDED WARRANTS EXERCISABLE INTO SHARES OF COMMON STOCK, SERIES A WARRANTS EXERCISABLE INTO SHARES OF COMMON STOCK AND SERIES B WARRANTS EXERCISABLE INTO SHARES OF COMMON STOCK OF SALARIUS PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT August , 2025 Ladenburg Thalmann & Co. Inc. As the Representative of the Several underwriters, if any, named in Schedule I her |
|
| July 31, 2025 |
Unregistered Sales of Equity Securities, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commi |
|
| July 31, 2025 |
Form of Series B Common Warrant to Purchase Shares of Common Stock Exhibit 4.13 SERIES B COMMON STOCK PURCHASE WARRANT SALARIUS PHARMACEUTICALS, INC. Warrant Shares: Issue Date: , 2025 CUSIP: ISIN: THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO., or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| July 31, 2025 |
Exhibit 4.9 PRE-FUNDED COMMON STOCK PURCHASE WARRANT SALARIUS PHARMACEUTICALS, INC. Warrant Shares: Issue Date: , 2025 CUSIP: ISIN: THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO., or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| July 31, 2025 |
Common Warrant to Purchase Shares of Common Stock Exhibit 4.12 SERIES A COMMON STOCK PURCHASE WARRANT SALARIUS PHARMACEUTICALS, INC. Warrant Shares: Issue Date: , 2025 CUSIP: ISIN: THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO., or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| July 31, 2025 |
Form of Warrant Agency Agreement Exhibit 4.11 Salarius Pharmaceuticals, Inc. and Equiniti Trust Company, LLC, as Warrant Agent Warrant Agency Agreement Dated as of , 2025 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2025 (“Agreement”), between Salarius Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC, a New York limited liability trust company (the “Warrant Agent”) |
|
| July 31, 2025 |
Form of Representative Warrant Exhibit 4.10 REPRESENTATIVE COMMON STOCK PURCHASE WARRANT SALARIUS PHARMACEUTICALS, INC. Warrant Shares: Issue Date: , 2025 THIS REPRESENTATIVE COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, , or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the d |
|
| July 31, 2025 |
Calculation of Filing Fee Tables S-1 Salarius Pharmaceuticals, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effe |
|
| July 31, 2025 |
Form of Note Exchange Agreement with certain Decoy Therapeutics, Inc. 2023 Promissory Noteholders Exhibit 10.33 July [ ], 2025 Attention Decoy Therapeutics, Inc. Promissory Note Holder Via email Re: Confidential Letter Agreement to Convert Original Issue Discount Promissory Notes Issued by Decoy Therapeutics, Inc. under 2023 Securities Purchase Agreements and Original Issue Discount Senior Unsecured Promissory Notes Issued by Decoy Therapeutics, Inc. under that certain Securities Purchase Agre |
|
| July 31, 2025 |
Form of Note Exchange Agreement with certain Decoy Therapeutics, Inc. Exhibit 10.32 July [ ], 2025 Attention Decoy Therapeutics, Inc. Promissory Note Holder Via email Re: Confidential Letter Agreement to Convert Promissory Notes Issued by Decoy Therapeutics, Inc. (Promissory Note dated ) Dear Decoy Therapeutics, Inc. Note Holder: As you are aware, Decoy Therapeutics, Inc. (“Decoy,” or the “Company”) and Salarius Pharmaceuticals, Inc. (“Salarius”), a Nasdaq-listed pu |
|
| July 31, 2025 |
As filed with the Securities and Exchange Commission on July 31, 2025 As filed with the Securities and Exchange Commission on July 31, 2025 Registration No. |
|
| July 29, 2025 |
Salarius Pharmaceuticals, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Mark J. Rosenblum, does hereby certify that: 1. He is the Executive Vice President Finance and Chief Financial Officer, of Salarius Pharmaceuticals, Inc., a Delaware corpo |
|
| July 29, 2025 |
Execution Version FOURTH AMENDMENT TO AGREEMENT AND PLAN OF MERGER THIS FOURTH AMENDMENT TO AGREEMENT AND PLAN OF MERGER (this “Fourth Amendment”) is entered into and made effective as of July 29, 2025 (the “Effective Date”), by and among Salarius Pharmaceuticals, Inc. |
|
| July 29, 2025 |
Salarius Pharmaceuticals, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Mark J. Rosenblum, does hereby certify that: 1. He is the Executive Vice President Finance and Chief Financial Officer, of Salarius Pharmaceuticals, Inc., a Delaware corpo |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commi |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commi |
|
| July 21, 2025 |
Form of Certificate of Designation of Series B Non-Voting Convertible Preferred Stock. Salarius Pharmaceuticals, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Mark J. Rosenblum, does hereby certify that: 1. He is the Executive Vice President Finance and Chief Financial Officer, of Salarius Pharmaceuticals, Inc., a Delaware corpo |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commi |
|
| July 21, 2025 |
Execution Version THIRD AMENDMENT TO AGREEMENT AND PLAN OF MERGER THIS THIRD AMENDMENT TO AGREEMENT AND PLAN OF MERGER (this “Third Amendment”) is entered into and made effective as of July 18, 2025 (the “Effective Date”), by and among Salarius Pharmaceuticals, Inc. |
|
| July 14, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commi |
|
| July 14, 2025 |
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard HOUSTON (July 14, 2025) – Salarius Pharmaceuticals, Inc. |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commis |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commi |
|
| June 16, 2025 |
As filed with the Securities and Exchange Commission on June 16, 2025 As filed with the Securities and Exchange Commission on June 16, 2025 Registration No. |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commi |
|
| June 11, 2025 |
Honigman Draft 6.5 SECOND AMENDMENT TO AGREEMENT AND PLAN OF MERGER THIS SECOND AMENDMENT TO AGREEMENT AND PLAN OF MERGER (this “Second Amendment”) is entered into and made effective as of June 10, 2025 (the “Effective Date”), by and among Salarius Pharmaceuticals, Inc., a Delaware corporation (“Parent”), Decoy Therapeutics MergerSub I, Inc., a Delaware corporation and wholly owned subsidiary of P |
|
| June 11, 2025 |
Form of Certificate of Designation of Series A Non-Voting Convertible Preferred Stock. Salarius Pharmaceuticals, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Mark J. Rosenblum, does hereby certify that: 1. He is the Executive Vice President Finance and Chief Financial Officer, of Salarius Pharmaceuticals, Inc., a Delaware corpo |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 22, 2025 |
As filed with the Securities and Exchange Commission on May 21, 2025 As filed with the Securities and Exchange Commission on May 21, 2025 Registration No. |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 14, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 0 |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Comm |
|
| April 17, 2025 |
Exhibit 10.28 Gates Foundation AMENDMENT 2 to GRANT AGREEMENT Investment ID INV-027470 AMENDMENT SUMMARY PAGE AMENDMENT INFORMATION Agreement to be Amended: Grant agreement between the Gates Foundation, formerly known as the Bill & Melinda Gates Foundation, and Decoy Therapeutics, Inc, effective September 9, 2021, as amended, and bearing Investment ID INV-027470 Amendment Purpose: No cost extensio |
|
| April 17, 2025 |
Exhibit 10.31 March 11, 2024 Barbara Hibner Decoy Therapeutics Inc. One Broadway, 14th Floor, Cambridge MA 02142 Re: BLUE KNIGHT™ Resident QuickFire Challenge: Partnering for Preparedness Dear Barbara Congratulations on your successful application for the BLUE KNIGHT™ Resident QuickFire Challenge: Partnering for Preparedness (the “QFC”). This letter will set forth the agreement (the “Agreement”) b |
|
| April 17, 2025 |
As filed with the Securities and Exchange Commission on April 16, 2025 As filed with the Securities and Exchange Commission on April 16, 2025 Registration No. |
|
| April 17, 2025 |
Exhibit 10.26 GRANT AGREEMENT Investment ID INV-027470 AGREEMENT SUMMARY & SIGNATURE PAGE GRANTEE INFORMATION Name: Decoy Therapeutics, Inc Tax Status: Not exempt from federal income tax under U.S. IRC § 501(c)(3) You confirm that the above information is correct and agree to notify the Foundation immediately of any change. Expenditure Responsibility: This Agreement is subject to "expenditure resp |
|
| April 17, 2025 |
Exhibit 10.30 July 28, 2023 Frederick Pierce Decoy Therapeutics, Inc. One Broadway, 14th floor Cambridge MA 02142 Re: BLUE KNIGHT™ Resident QuickFire Challenge: Accelerating Project NextGen Dear Frederick, Congratulations on your successful application for the BLUE KNIGHT™ Resident QuickFire Challenge: Accelerating Project NextGen (the “QFC”). This letter will set forth the agreement (the "Agreeme |
|
| April 17, 2025 |
Exhibit 10.27 AMENDMENT 1 to GRANT AGREEMENT Investment ID INV-027470 AMENDMENT SUMMARY & SIGNATURE PAGE AMENDMENT INFORMATION Agreement to be Amended: Grant agreement between the Bill & Melinda Gates Foundation and Decoy Therapeutics, Inc, effective September 9, 2021, and bearing Investment ID INV- 027470 Amendment Purpose: Supplement and Term Extension Amendment Date: Date of last signature Amen |
|
| April 17, 2025 |
Exhibit 10.29 January 31, 2023 Peter Marschel Decoy Therapeutics Inc. One Broadway, 14th Floor, Cambridge MA 02142 Re: BLUE KNIGHT™ Resident QuickFire Challenge Dear Peter, Congratulations on your successful application for the BLUE KNIGHT™ Resident QuickFire Challenge (the “QFC”). This letter will set forth the agreement (the "Agreement") between us, Johnson & Johnson Innovation LLC (“JJI”) and D |
|
| March 28, 2025 |
Execution Version FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER THIS FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER (this “First Amendment”) is entered into and made effective as of March 28, 2025 (the “Effective Date”), by and among Salarius Pharmaceuticals, Inc. |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Comm |
|
| March 21, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ———————–––––————————— FORM 10-K ———————————— (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period fro |
|
| March 21, 2025 |
Execution Copy AMENDMENT 1 TO CONSULTING AGREEMENT This Amendment 1 to Consulting Agreement ("Consulting Agreement") dated February 20, 2024 is effective as of February 20, 2025 (the "Effective Date") by and between Salarius Pharmaceuticals, Inc. |
|
| March 21, 2025 |
Salarius Pharmaceuticals, Inc. Insider Trading Policy SALARIUS PHARMACEUTICALS, INC. INSIDER TRADING AND COMMUNICATIONS POLICY Policy as to Trades in the Company’s Securities By Company Personnel and Treatment of Confidential Information 1.Purpose. Both the Securities and Exchange Commission (the “SEC”) and Congress are very concerned about maintaining the fairness and integrity of the U.S. capital markets. The securities laws are continually reviewe |
|
| March 11, 2025 |
Exhibit 107 The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of that offering is $50,000,000. |
|
| March 11, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Comm |
|
| March 11, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-266589 PROSPECTUS SUPPLEMENT (To the Prospectus Dated August 16, 2022) Up to $417,000 Common Stock We previously entered into an At the Market Offering Agreement dated as of February 5, 2021, or the sales agreement, with Ladenburg Thalmann & Co. Inc., or Ladenburg, relating to shares of our common stock, par value $0.0001 per share, offered by |
|
| January 21, 2025 |
Consent of Barbara Hibner to be named as a director Exhibit 99.1 January 11, 2025 Salarius Pharmaceuticals, Inc. 2450 Holcombe Blvd., Suite X Houston, TX 77021 Consent to Reference in Registration Statement Salarius Pharmaceuticals, Inc. (the “Company”) has filed the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby co |
|
| January 21, 2025 |
Consent of Frederick Pierce to be named as a director Exhibit 99.2 January 11, 2025 Salarius Pharmaceuticals, Inc. 2450 Holcombe Blvd., Suite X Houston, TX 77021 Consent to Reference in Registration Statement Salarius Pharmaceuticals, Inc. (the “Company”) has filed the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby co |
|
| January 21, 2025 |
As filed with the Securities and Exchange Commission on January 21, 2025 As filed with the Securities and Exchange Commission on January 21, 2025 Registration No. |
|
| January 21, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Salarius Pharmaceuticals, Inc. |
|
| January 17, 2025 |
Unregistered Sales of Equity Securities, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Co |
|
| January 13, 2025 |
Exhibit 99.4 Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement Decoy’s proprietary IMP3ACT™ peptide conjugate drug design and manufacturing platform leverages machine learning (ML) and artificial intelligence (AI) tools Decoy is leveraging non-dilutive funding and equivalents from federal governments, corporations and The Bill & Melinda Gates Foundation totaling |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Co |
|
| January 13, 2025 |
Exhibit 10.4 Warrant Cancellation Agreement This Warrant Cancellation Agreement (the “Agreement”) is made and entered into as of January 10, 2025, by and between Salarius Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned holder of the Existing Warrants (as defined below) (the “Holder”). Recitals A.The Holder previously acquired those certain Common Stock Purchase W |
|
| January 13, 2025 |
Exhibit 10.2 FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT DECOY THERAPEUTICS, INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”) dated as of January , 2025, is made by and among Decoy Therapeutics, Inc., a Delaware corporation (the “Company”), Salarius Pharmaceuticals, Inc., a Delaware corporation (“Parent”), and the undersigned holder ( “Stockholder”) of shares of capital stock (th |
|
| January 13, 2025 |
Exhibit 10.1 FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT SALARIUS PHARMACEUTICALS, INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of January [ ], 2025, is made by and among Salarius Pharmaceuticals, Inc., a Delaware corporation (“Parent”), Decoy Therapeutics Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital st |
|
| January 13, 2025 |
Exhibit 4.1 Salarius Pharmaceuticals, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Mark J. Rosenblum, does hereby certify that: 1. He is the Executive Vice President Finance and Chief Financial Officer, of Salarius Pharmaceuticals, Inc., a De |
|
| January 13, 2025 |
UNAUDITED PRO FORMA CONSOLIDATED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONSOLIDATED COMBINED FINANCIAL INFORMATION The following unaudited pro forma consolidated combined financial information is provided to aid you in your analysis of the financial aspects of the Merger and Financing Transactions and presents the combination of the financial information of Salarius and Decoy adjusted to give effect to the Merger and Financing Transac |
|
| January 13, 2025 |
Exhibit 10.3 Form of Lock-Up Agreement [●], 2025 Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Salarius Pharmaceuticals, Inc., a Delaware corporation (including any successor thereto, “Parent”), has entered into an Agreement and Plan of Merger, dated as of [●], 2025 (as the same may be amended from time to time, the “Merger Ag |
|
| January 13, 2025 |
Consolidated Financial Statements Nine months ended September 30, 2024 and 2023 F-2 DECOY THERAPEUTICS, INC. |
|
| January 13, 2025 |
a991fs2022and2023 Consolidated Financial Statements Years Ended December 31, 2023 and 2022 DECOY THERAPEUTICS, INC. |
|
| January 13, 2025 |
Up to 6,733,334 Shares of Common Stock PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-283828 Up to 6,733,334 Shares of Common Stock This prospectus relates to the potential resale from time to time by C/M Capital Master Fund, LP, or the Selling Stockholder, of up to 6,733,334 shares of common stock, par value $0.0001 per share, or common stock. The shares of common stock to which this prospectus relates consists of sh |
|
| January 13, 2025 |
Exhibit 2.1 Agreement and Plan of Merger by and among Salarius Pharmaceuticals, Inc., a Delaware corporation; Decoy Therapeutics MergerSub I, Inc., a Delaware corporation; Decoy Therapeutics MergerSub II, LLC, a Delaware limited liability company; and Decoy Therapeutics Inc., a Delaware corporation. Dated as of January 10, 2025 TABLE OF CONTENTS Page 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger |
|
| December 26, 2024 |
SALARIUS PHARMACEUTICALS, INC. 2450 Holcombe Blvd., Suite X Houston, Texas 77021 SALARIUS PHARMACEUTICALS, INC. 2450 Holcombe Blvd., Suite X Houston, Texas 77021 December 26, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Salarius Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed December 16, 2024 File No. 333-283828 Request for Acceleration of Effective D |
|
| December 23, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (C |
|
| December 16, 2024 |
As filed with the Securities and Exchange Commission on December 13, 2024 As filed with the Securities and Exchange Commission on December 13, 2024 Registration No. |
|
| December 16, 2024 |
\\4152-0412-7830 v5 Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Salarius Pharmaceuticals, Inc. |
|
| December 13, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 12, 2024 (the “Execution Date”), is entered into by and between SALARIUS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and C/M CAPITAL MASTER FUND, LP, a Delaware limited partnership (together with its permitted assigns, the “Buyer”). Capitalized terms used herein |
|
| December 13, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 12, 2024 (the “Execution Date”), by and between SALARIUS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and C/M CAPITAL MASTER FUND, LP, a Delaware limited partnership (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Co |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (C |
|
| November 14, 2024 |
SLRX / Salarius Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-slrx093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* SALARIUS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 79400X404 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check |
|
| November 14, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Numbe |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| September 27, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2024 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 15, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 00 |
|
| July 25, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 25, 2024 |
Exhibit 107.1 The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of that offering is $50,000,000. |
|
| July 25, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-266589 PROSPECTUS SUPPLEMENT (To the Prospectus Dated August 16, 2022) Up to $335,921 Common Stock We previously entered into an At the Market Offering Agreement dated as of February 5, 2021, or the sales agreement, with Ladenburg Thalmann & Co. Inc., or Ladenburg, relating to shares of our common stock, par value $0.0001 per share, offered by |
|
| July 23, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 22, 2024 |
Exhibit 107.1 The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of that offering is $50,000,000. |
|
| July 22, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-266589 PROSPECTUS SUPPLEMENT (To the Prospectus Dated August 16, 2022) Up to $810,973 Common Stock We previously entered into an At the Market Offering Agreement dated as of February 5, 2021, or the sales agreement, with Ladenburg Thalmann & Co. Inc., or Ladenburg, relating to shares of our common stock, par value $0.0001 per share, offered by |
|
| July 19, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 11, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 17, 2024 |
Exhibit 107.1 The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of that offering is $50,000,000. |
|
| June 17, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-266589 PROSPECTUS SUPPLEMENT (To the Prospectus Supplement Dated August 16, 2022 and the Prospectus Dated August 16, 2022) Up to $536,250 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated August 16, 2022 (the “Prospectus”) filed with the Securities and Exchange Commission as a part of our re |
|
| June 17, 2024 |
Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14 predominantly higher risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) patients who previously failed or relapsed after hypomethylating agent therapy Median overall survival was 18. |
|
| June 17, 2024 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 14, 2024 |
DocuSign Envelope ID: 5835E6DF-9B7A-4545-ACF0-BF833E74D2C3 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SALARIUS PHARMACEUTICALS, INC. |
|
| June 14, 2024 |
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split HOUSTON (June 12, 2024) – Salarius Pharmaceuticals, Inc. |
|
| June 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 13, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 0 |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 22, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ———————–––––————————— FORM 10-K ———————————— (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period fro |
|
| March 22, 2024 |
Salarius Pharmaceuticals, Inc., Clawback Policy SALARIUS PHARMACEUTICALS, INC. Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Salarius Pharmaceuticals, Inc. (the “Company”) on November 17, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the best inter |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 6, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 23, 2024 |
INDEMNIFICATION AGREEMENT This Indemnification Agreement (the “Agreement”), dated as of February 20, 2024, between Salarius Pharmaceuticals, Inc. |
|
| February 23, 2024 |
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is entered into by and between SALARIUS PHARMACEUTICALS, INC. |
|
| February 23, 2024 |
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses Company implementing a series of cost-savings measures designed to extend Salarius’ expected cash runway into the first half of 2025 Extended runway supports the generation of additional data from the ongoing Phase 1/2 clinical trials in hematologic cancers and Ewing sarcoma HOUSTON (February 22, 2024) – Salarius Pharmaceuticals, Inc. |
|
| February 23, 2024 |
CONSULTING AGREEMENT This Consulting Agreement (“Consulting Agreement”) is effective as of February 20, 2024 (the “Effective Date”) by and between Salarius Pharmaceuticals, Inc. |
|
| February 23, 2024 |
SALARIUS PHARMACEUTICALS, INC. NOTICE OF STOCK OPTION AMENDMENT February 20, 2024 To: David Arthur [***] [***] Salarius Pharmaceuticals, Inc. (the “Company” is pleased to announce that on February 20, 2024, the Board of Directors of the Company (the “Board”) amended your stock options granted on September 10, 2019, March 23, 2020, July 14, 2020, December 2, 2020, and January 20, 2022 (the “Options |
|
| February 23, 2024 |
SEPARATION AGREEMENT AND GENERAL RELEASE This Confidential Separation Agreement and General Release (the “Agreement”) is being entered into between DAVID J. |
|
| February 23, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File |
|
| February 14, 2024 |
US79400X3052 / SALARIUS PHARMACEUTICALS INC / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-slrx123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SALARIUS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 79400X305 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| November 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Numbe |
|
| October 27, 2023 |
US79400X3052 / SALARIUS PHARMACEUTICALS INC / Lee Elvin Sanghwan - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Salarius Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.0001 par value (Title of Class of Securities) 79400X305 (CUSIP Number) Elvin Lee 31 Bilton St. Teaneck, NJ 07666 (818) 455 5759 (Name, Address and Telephone Number of Person Authorized to Re |
|
| September 6, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File |
|
| August 10, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 00 |
|
| August 10, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 10, 2023 |
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update FDA removed partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat SP-3164 targeted protein degrader received Investigational New Drug clearance from FDA Company to explore strategic alternatives and implement measures to extend its resources HOUSTON (August 10, 2023) – Salarius Pharmaceuticals, Inc. |
|
| July 12, 2023 |
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients The trial will assess the safety and preliminary efficacy of Salarius’ novel targeted protein degrader SP-3164; Patient dosing expected to begin in 2H 2023 The trial will also assess the utility of a gene signature to identify patients that are potentially sensitized to SP-3164 treatment and may be more likely to respond HOUSTON (July 11, 2023) – Salarius Pharmaceuticals, Inc. |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2023 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commi |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commi |
|
| June 15, 2023 |
SALARIUS PHARMACEUTICALS, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN As Amended and Restated effective as of June 14, 2023 1.GENERAL; PURPOSE. (a)The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Emp |
|
| June 7, 2023 |
11,163,637 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-272249 PROSPECTUS 11,163,637 Shares of Common Stock The selling stockholders named in this prospectus may use this prospectus to offer and resell from time to time up to 11,163,637 shares of our common stock, par value $0.0001 per share, which are comprised of (i) 330,000 shares (the “Shares”) of our common stock issued in a private placement o |
|
| June 2, 2023 |
SALARIUS PHARMACEUTICALS, INC. 2450 Holcombe Blvd., Suite X Houston, Texas 77021 SALARIUS PHARMACEUTICALS, INC. 2450 Holcombe Blvd., Suite X Houston, Texas 77021 June 2, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Salarius Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 26, 2023 File No. 333-272249 Request for Acceleration of Effective Date Ladies |
|
| June 1, 2023 |
As filed with the Securities and Exchange Commission on June 1, 2023 As filed with the Securities and Exchange Commission on June 1, 2023 Registration Statement No. |
|
| May 26, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Salarius Pharmaceuticals, Inc. |
|
| May 26, 2023 |
As filed with the Securities and Exchange Commission on May 26, 2023 As filed with the Securities and Exchange Commission on May 26, 2023 Registration Statement No. |
|
| May 16, 2023 |
Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules HOUSTON (May 16, 2023) – Salarius Pharmaceuticals, Inc. |
|
| May 16, 2023 |
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commis |
|
| May 16, 2023 |
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 11, 2023, between Salarius Pharmaceuticals, Inc. |
|
| May 16, 2023 |
Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules HOUSTON (May 12, 2023) – Salarius Pharmaceuticals, Inc. |
|
| May 16, 2023 |
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| May 16, 2023 |
REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 11, 2023, between Salarius Pharmaceuticals, Inc. |
|
| May 16, 2023 |
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| May 11, 2023 |
Exhibit 31.2 Certification Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Mark J. Rosenblum, Executive Vice President and Interim Chief Financial Officer, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Salarius Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not cont |
|
| May 11, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 0 |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 27, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ———————–––––————————— FORM 10-K ———————————— (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period fro |
|
| March 13, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 15, 2023 |
As filed with the Securities and Exchange Commission on February 15, 2023 As filed with the Securities and Exchange Commission on February 15, 2023 Registration No. |
|
| February 15, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Salarius Pharmaceuticals, Inc. |
|
| February 13, 2023 |
SC 13G/A 1 sc13ga.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Salarius Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 79400X305 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Stateme |
|
| February 13, 2023 |
EX-99.1 2 exhibit99-1.htm JOINT FILING APPLICATION BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING APPLICATION The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.0001 per share, of Salarius Pharmaceuticals, Inc., shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an ex |
|
| January 10, 2023 |
Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders Expands intellectual property portfolio with composition-of-matter patent protection for second novel molecular glue Protein degrader intellectual property portfolio now includes 16 issued patents across six unique patent families HOUSTON (January 5, 2023) – Salarius Pharmaceuticals, Inc. |
|
| January 10, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2023 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 1, 2022 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File |
|
| December 1, 2022 |
Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas 60% Confirmed Disease Control Rate1 and 7. |
|
| November 10, 2022 |
Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update HOUSTON (November 10, 2022) – Salarius Pharmaceuticals, Inc. |
|
| November 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File |
|
| November 10, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Numbe |
|
| November 3, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File |
|
| October 27, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File |
|
| October 27, 2022 |
salariustpd5thconf © 2022 Salarius Pharmaceuticals, Inc. Non Confidential SP-3164, a cereblon-binding molecular glue 5th Annual Targeted Protein Degradation Summit October 26, 2022 © 2022 Salarius Pharmaceuticals, Inc. Non Confidential Safe Harbor Statement 2 This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All stat |
|
| October 27, 2022 |
Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference Data showcased novel compound with potential for improved anti-cancer activity over other molecular glues Salarius plans to release additional preclinical results at the American Society of Hematology annual meeting later this year HOUSTON (October 27, 2022) – Salarius Pharmaceuticals, Inc. |
|
| October 18, 2022 |
Press Release of Salarius Pharmaceuticals, Inc., dated October Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas HOUSTON (October 18, 2022) ? Salarius Pharmaceuticals, Inc. |
|
| October 18, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File |
|
| October 14, 2022 |
Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split HOUSTON, Oct. 14, 2022 (GLOBE NEWSWIRE) ? Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of new treatment options, today announced that it will effect a 1-for-25 reverse stock split at 5:00 p.m. Eastern time today. Beginning with t |
|
| October 14, 2022 |
CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF SALARIUS PHARMACEUTICALS, INC. |
|
| October 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2022 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File |
|
| August 15, 2022 |
Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Multiple development and data milestones expected from seclidemstat and SP-3164 programs in 2H22 Conference call and webcast today at 11:00 a. |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 12, 2022 |
SALARIUS PHARMACEUTICALS, INC. 2450 Holcombe Blvd., Suite X Houston, Texas 77021 SALARIUS PHARMACEUTICALS, INC. 2450 Holcombe Blvd., Suite X Houston, Texas 77021 August 12, 2022 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Salarius Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 5, 2022 File No. 333-266589 Request for Acceleration of Effective Date Ladies and Gentlemen: Pur |
|
| August 5, 2022 |
As filed with the Securities and Exchange Commission on August 5, 2022 As filed with the Securities and Exchange Commission on August 5, 2022 Registration No. |
|
| August 5, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 00 |
|
| August 5, 2022 |
Form of Indenture (filed herewith). Exhibit 4.7 SALARIUS PHARMACEUTICALS, INC. and as Trustee INDENTURE Dated as of , ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 Definitions 1 1.2 Other Definitions 5 1.3 Incorporation by Reference of Trust Indenture Act 5 1.4 Rules of Construction 6 ARTICLE 2 THE SECURITIES 6 2.1 Issuable in Series 6 2.2 Establishment of Terms of Series of Securities 7 2.3 Execution and Authentication |
|
| August 5, 2022 |
Filing Fee Table (filed herewith). EX-FILING FEES 2 exhibit107-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Salarius Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit |
|
| August 3, 2022 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 3, 2022 |
Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement HOUSTON, Texas (August 2, 2022) ? Salarius Pharmaceuticals, Inc. |
|
| June 21, 2022 |
SALARIUS PHARMACEUTICALS, INC. 2450 Holcombe Blvd., Suite X Houston, Texas 77021 SALARIUS PHARMACEUTICALS, INC. 2450 Holcombe Blvd., Suite X Houston, Texas 77021 June 21, 2022 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Salarius Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-265535) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of |
|
| June 17, 2022 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 10, 2022 |
As filed with the Securities and Exchange Commission on June 10, 2022 As filed with the Securities and Exchange Commission on June 10, 2022 Registration Statement No. |
|
| June 10, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Salarius Pharmaceuticals, Inc. |
|
| May 12, 2022 |
Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results Salarius Successfully Completes SP-3164 Pre-IND Meeting Process with FDA Advancing multiple drug development programs, led by SP-3164 in targeted protein degradation, and seclidemstat in protein inhibition, a clinical-stage reversible LSD1 inhibitor Multiple potential development and data milestones expected from both programs in 2H 2022 2022 Annual Meeting of Stockholders announced for June 15, 2022; Company is encouraging all stockholders to participate and vote their shares of Salarius Pharmaceuticals stock. |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 12, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 0 |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| May 6, 2022 |
Salarius Pharmaceuticals, Inc. 2450 Holcombe Blvd., Suite X Houston, TX 77021 Salarius Pharmaceuticals, Inc. 2450 Holcombe Blvd., Suite X Houston, TX 77021 May 6, 2022 VIA EDGAR Division of Corporate Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attn: Christie Wong and Brian Cascio Re: Salarius Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed March 25, 2022 File No. 0 |
|
| April 29, 2022 |
SLRX / Salarius Pharmaceuticals Inc / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Salarius Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 79400X107 (CUSIP Number) April 26, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| April 29, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.0001 per share, of Salarius Pharmaceuticals, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. April 29, 2022 LIND GLOBAL FUND II LP By: Lind Global Partner |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 27, 2022 |
EXHIBIT 1 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). |
|
| April 27, 2022 |
SLRX / Salarius Pharmaceuticals Inc / Lincoln Park Capital Fund, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SALARIUS PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 79400X107 (CUSIP Number) April 22, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| April 26, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-231010 PROSPECTUS SUPPLEMENT (To Prospectus dated May 17, 2019) 9,339,436 Shares Common Stock We are offering 9,339,436 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus to certain institutional investors. Our common stock is traded on the Nasdaq Capital Market under the symbol ?SLRX.? On April 21 |
|
| April 26, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Comm |
|
| April 26, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Salarius Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock 457( |
|
| April 22, 2022 |
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of April 22, 2022, between Salarius Pharmaceuticals, Inc. |
|
| April 22, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2022 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 22, 2022 |
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering HOUSTON, April 22, 2022 (GLOBE NEWSWIRE) ? Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that it has entered into definitive agreements with several institutional investors for the pur |
|
| April 22, 2022 |
VOTING AGREEMENT This Voting Agreement (this ?Voting Agreement?), dated April 25, 2022, is being delivered to you in connection with an understanding by and between Salarius Pharmaceuticals, Inc. |
|
| April 22, 2022 |
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 1, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2022 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 1, 2022 |
Amendment to Amended and Restated Bylaws of the Registrant, effective April 1, 2022 AMENDMENT TO AMENDED AND RESTATED BYLAWS OF SALARIUS PHARMACEUTICALS, INC. (A DELAWARE CORPORATION) (Effective April 1, 2022) On April 1, 2022, the Board of Directors of Salarius Pharmaceuticals, Inc. approved the amendment of Section 2.7 of Article II of the Bylaws of the corporation to read as follows: 2.7 Quorum. Except where otherwise provided by law or the certificate of incorporation of the |
|
| March 25, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ????????????????????? FORM 10-K ???????????? (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period fro |
|
| March 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 10, 2022 |
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results Strategic acquisition of SP-3164, a targeted protein degrader in development for hematologic and solid tumors, adds to pipeline of cancer therapies Clinical development of seclidemstat is continuing with updates from two Phase 1/2 clinical trials in sarcoma and hematologic cancer patients anticipated in 2022 Conference Call and Live Audio Webcast Scheduled for Today, March 10, 2022, 5:00 p. |
|
| February 22, 2022 |
Calculation of Filing Fee Table EX-FILING FEES 2 salarius-sx8exhibit107.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Salarius Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fe |
|
| February 22, 2022 |
HL Draft February 17, 2022 SALARIUS PHARMACEUTICALS, INC. 2015 EQUITY INCENTIVE PLAN RESTICTED STOCK GRANT NOTICE Unless otherwise defined herein, the terms defined in the Salarius Pharmaceuticals, Inc. 2015 Equity Incentive Plan (the ?Plan?) shall have the same defined meanings in the Restricted Stock Grant Notice (the ?Grant Notice?) and the Restricted Stock Agreement with any appendices and exh |
|
| February 22, 2022 |
As filed with the Securities and Exchange Commission on February 22, 2022 As filed with the Securities and Exchange Commission on February 22, 2022 Registration No. |
|
| February 10, 2022 |
CUSIP No. 79400X107 Page 1 of 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 Salarius Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $ 0.0001 par value (Title of Class of Securities) 79400X107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| January 13, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2022 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File |
|
| January 13, 2022 |
Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC Conference call and live audio webcast scheduled for today at 8:30 a. |
|
| January 13, 2022 |
Acquisition and Strategic Collaboration Agreement, dated January 12, 2022. Exhibit 10.1 ***Certain identified information has been omitted from this exhibit in accordance with the rules of the Securities and Exchange Commission because it is both (i) not material to investors and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (?[*****]?) in this exhibit*** EXECUTION COPY ACQUISITION AND STRATEGIC |
|
| November 19, 2021 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2021 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File |
|
| November 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Numbe |
|
| September 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2021 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 20, 2021 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2021 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 5, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 00 |
|
| August 5, 2021 |
Salarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress Clinical Trial in Hematologic Cancers Initiated and Initial Patients Enrolled in Expanded Sarcoma Clinical Trial; Multiple Potential Data Readouts Expected in 2021 and 2022 Preliminary Efficacy Findings from Sarcoma and Advanced Solid Tumor Trials Presented at American Society of Clinical Oncology Cash and Cash Equivalents of $33. |
|
| July 2, 2021 |
Consent of Hogan Lovells US LLP (contained in Exhibit 5.1). Hogan Lovells US LLP 609 Main Street, Suite 4200 Houston, TX 77002 T +1 713 632 1400 F +1 713 632 1401 www. |
|
| July 2, 2021 |
Salarius Pharmaceuticals, Inc. Up to $25,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-231010 PROSPECTUS SUPPLEMENT (To Prospectus dated May 17, 2019) Salarius Pharmaceuticals, Inc. Up to $25,000,000 Common Stock We previously entered into a sales agreement with Ladenburg Thalmann & Co. Inc., or Ladenburg, dated February 5, 2021, relating to shares of our common stock offered by this prospectus supplement and the accompanying pro |
|
| July 2, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2021 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 1, 2021 |
Consent of Hogan Lovells US LLP (contained in Exhibit 5.1). Hogan Lovells US LLP 609 Main Street, Suite 4200 Houston, TX 77002 T +1 713 632 1400 F +1 713 632 1401 www. |
|
| July 1, 2021 |
COMMON STOCK PURCHASE WARRANT SALARIUS PHARMACEUTICALS, INC. Warrant Shares: [Number of shares] Issue Date: [?] THIS COMMON STOCK PURCHASE WARRANT (this ?Warrant?) certifies that, for value received, [stockholder name] (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date and |
|
| July 1, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 1, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-231010 PROSPECTUS SUPPLEMENT (To Prospectus dated May 17, 2019) Warrants to purchase up to 142,711 shares of common stock and Up to 142,711 shares of common stock issuable upon the exercise of the Warrants As previously disclosed, we entered into that certain Agreement and Plan of Merger dated January 3, 2019 (as amended, the ?Merger Agreement? |
|
| June 16, 2021 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36812 46-5087339 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 20, 2021 |
Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Preliminary drug activity observed in both relapsed/refractory Ewing sarcoma and Advanced Solid Tumor (AST) trials Presentations include full data from dose-escalation stage of Phase 1/2 clinical trial evaluating seclidemstat in Ewing sarcoma and preliminary data from ongoing AST trial HOUSTON, May 19, 2021 (GLOBE NEWSWIRE) ? Salarius Pharmaceuticals, Inc. |
|
| May 20, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36812 (Commission File N |
|
| May 12, 2021 |
EX-99.1 2 salarius-x1q2021earningspr.htm EX-99.1 Salarius Pharmaceuticals Reports First Quarter Financial Results with Business Highlights Cash and Cash Equivalents of $36.6M, More Than Sufficient to Fund Completion of the Current Clinical Trials of Lead Drug Candidate, Seclidemstat Conference Call and Live Audio Webcast Scheduled for Today, Wednesday, May 12, 2021, 5:00 p.m. ET HOUSTON, May 12, 2 |
|
| May 12, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 0 |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36812 (Commission File N |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
